Palbociclib Capsule: A Bioequivalence Study in Healthy Subjects Under Fed Conditions to Compare Two Formulations

<b>Background:</b> Globally, breast cancer is the most frequently diagnosed neoplasm among women, with an estimated 2.3 million new cases reported in 2022. Treatment for hormone receptor-positive (HR+) advanced breast cancer includes aromatase inhibitors and CDK4/6 inhibitors such as palbociclib. <b...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Marcelo Gomes Davanço, Thaís Pereira Vespasiano, Jessé Moisan, Maira Eduarda Zanin, Gilberto Carlos Ruggiero Bernasconi, Marcia Aparecida Antonio, Oscar Gonzalez, Milesa Sarmiento, Mélanie Groleau
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	MDPI AG 2026-01-01
Σειρά:	Pharmaceutics
Θέματα:	palbociclib bioequivalence pharmacokinetics bioavailability generics advanced breast cancer
Διαθέσιμο Online:	https://www.mdpi.com/1999-4923/18/2/175
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!